Skip to main content
    P

    Prelude Therapeutics Inc (PRLD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.41
    -0.04 (-1.16%)

    Market Cap: $275.32M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Prelude Therapeutics Inc (PRLD) Financials: Revenue, Profit and Cash Flow

    Updated Nov 11, 2026. Financial statements from company filings, amounts in US dollars.

    Prelude Therapeutics reported revenue of $12.14M for the fiscal year ended Dec 31, 2025, up 73.4% from the year before. That year, net income was -$99.50M with a net margin of -819.6%, operating cash flow was -$56.30M and free cash flow was -$56.37M. The quarter ended Sep 30, 2026 had revenue of $5.65M and net income of -$12.54M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$12.14M+73.4%100.0%-861.3%-819.6%
    Dec 2024$7.00MN/A100.0%-1995.9%-1816.8%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$12.14M$7.00M$0$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$149.00K
    Gross profit$12.14M$7.00M$0$0$0$0$0-$149.00K
    Research and development$94.30M$118.00M$103.39M$92.89M$86.78M$48.18M$24.28M$12.62M
    Operating income-$104.57M-$139.71M-$132.28M-$123.54M-$113.73M-$58.76M-$28.11M-$14.97M
    Net income-$99.50M-$127.17M-$121.83M-$115.44M-$111.69M-$56.93M-$27.57M-$14.68M
    EBITDA-$98.16M-$130.04MN/A-$111.52M-$109.42M-$56.39M-$27.19M-$14.83M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$5.65M$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0$3.42M
    Gross profit$5.65M$5.70M$4.58M$5.64M$6.50M$0$0$4.00M$3.00M$0$0-$331.00K
    Operating income-$14.27M-$15.45M-$14.18M-$17.35M-$20.42M-$32.19M-$34.61M-$33.83M-$34.38M-$37.16M-$34.34M-$37.38M
    Net income-$12.54M-$13.92M-$10.38M-$16.46M-$19.73M-$31.23M-$32.09M-$28.73M-$32.27M-$34.74M-$31.43M-$33.08M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.74M by $32.51M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$141.31M$175.51M$277.67M$220.50M$305.10M$223.59M$21.87M$16.41M
    Current assets$105.69M$135.90M$235.59M$204.38M$295.12M$220.81M$20.22M$15.60M
    Cash and equivalents$35.26M$12.47M$25.29M$30.61M$31.83M$218.31M$18.88M$15.60M
    Total liabilities$72.68M$44.06M$40.58M$25.06M$19.20M$11.41M$4.84M$39.10M
    Short-term debt$2.74M$2.70M$1.48M$1.83M$1.74MN/A$258.00KN/A
    Shareholder equity$68.64M$131.46M$237.09M$195.44M$285.90M$212.18M-$49.41M-$22.69M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$175.49M$189.36M$119.64M$141.31M$94.75M$114.92M$141.26M$175.51M$197.22M$224.29M$247.11M$277.67M
    Total liabilities$51.35M$55.63M$59.46M$72.68M$36.22M$39.08M$38.08M$44.06M$40.79M$42.02M$36.37M$40.58M
    Cash and equivalents$23.41M$26.33M$21.76M$35.26M$47.53M$25.75M$40.27M$12.47M$11.13M$27.83M$24.71M$25.29M
    Shareholder equity$124.14M$133.73M$60.18M$68.64M$58.53M$75.84M$103.18M$131.46M$156.43M$182.28M$210.73M$237.09M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$56.30M-$102.89M-$107.06M-$83.73M-$83.53M-$46.18M-$25.66M-$12.95M
    Capital expenditures$67.00K$764.00K$3.51M$3.02M$2.32M$621.00K$780.00K$529.00K
    Free cash flow-$56.37M-$103.65M-$110.58M-$86.75M-$85.85M-$46.80M-$26.45M-$13.48M
    Share repurchases$0$110.00K$2.80MN/A$303.00K$12.00K$0N/A
    Investing cash flow$53.46M$90.19M-$34.65M$81.69M-$263.80M-$621.00K-$780.00K-$529.00K
    Financing cash flow$24.82M-$120.00K$136.40M$815.00K$164.90M$246.23M$29.73M$17.94M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$13.78M-$15.57M-$21.68M$23.12M-$19.11M-$26.07M-$34.23M-$20.74M-$27.30M-$23.06M-$31.79M-$23.58M
    Capital expenditures$35.00KN/A$0$0$0$20.00K$47.00K$53.00K$63.00K$359.00K$289.00K$1.13M
    Free cash flow-$13.81MN/A-$21.68M$23.12M-$19.11M-$26.09M-$34.28M-$20.80M-$27.36M-$23.42M-$32.08M-$24.71M
    Last 12 quarters

    Frequently Asked Questions About PRLD

    What is Prelude Therapeutics' annual revenue?

    Prelude Therapeutics reported revenue of $12.14M for the fiscal year ended Dec 31, 2025.

    How fast is Prelude Therapeutics' revenue growing?

    Revenue was up 73.4% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Prelude Therapeutics profitable?

    No. Prelude Therapeutics reported net income of -$99.50M for the fiscal year ended Dec 31, 2025, with a net margin of -819.6%.

    How much free cash flow does PRLD generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$56.30M minus capital expenditures of $67.00K produced free cash flow of -$56.37M.

    How much debt does Prelude Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.74M and cash and equivalents of $35.26M.